ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-5173ometendo-5173Research ArticleСтатьиArticlesВисцеральное ожирение - ключевое звенометаболического синдромаVistseral'noe ozhirenie - klyuchevoe zvenometabolicheskogo sindromaButrovaS A-DzgoevaF Kh-20041503200411№1 (2004)1016Copyright © Butrova S.A., Dzgoeva F.K., 20042004Butrova S.A., Dzgoeva F.K.Butrova S.A., Dzgoeva F.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/5173ReferencesБутрова С. А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению. РМЖ 2001; 2 (9): 56-60.Бутрова С. А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению. РМЖ 2001; 2 (9): 56-60.Дедов И. И., Сунцов Ю. И., Кудрякова С. В. Эпидемиология сахарного диабета. В кн.: Сахарный диабет. Руководство для врачей. - М. - Универсум паблишинг 2003; 75-93.Дедов И. И., Сунцов Ю. И., Кудрякова С. В. Эпидемиология сахарного диабета. В кн.: Сахарный диабет. Руководство для врачей. - М. - Универсум паблишинг 2003; 75-93.Мельниченко Г.А. Ожирение в практике эндокринолога. РМЖ. 2001; 2 (9): 82- 87.Мельниченко Г.А. Ожирение в практике эндокринолога. РМЖ. 2001; 2 (9): 82- 87.Никитин Ю. П., Казека Г. Р., Симонова Г. И. Распространенность компонентов метаболического синдрома Х в неорганизованной городской популяции (эпидемиологическое исследование). Кардиология 2001; 9: 37-40.Никитин Ю. П., Казека Г. Р., Симонова Г. И. Распространенность компонентов метаболического синдрома Х в неорганизованной городской популяции (эпидемиологическое исследование). Кардиология 2001; 9: 37-40.Auwerx J, Mangelsdorf D. X-ceptors, nuclear receptors for metabolism. Excerpta Medica, Atherosclerosis XII 2000: 21-40.Auwerx J, Mangelsdorf D. X-ceptors, nuclear receptors for metabolism. Excerpta Medica, Atherosclerosis XII 2000: 21-40.Beck-Nielsen H. General characteristics of the insulin resistance syndrome: preva- lence and heritability European Group for the study of Insulin Resistance (EGIR). Drugs 1999; 58: 5-7.Beck-Nielsen H. General characteristics of the insulin resistance syndrome: preva- lence and heritability European Group for the study of Insulin Resistance (EGIR). Drugs 1999; 58: 5-7.Bergman R. Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia 2000; 43: 946-953.Bergman R. Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia 2000; 43: 946-953.Boden G, Shulman GI. Free acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and ®-cell dysfunction. Eur J Clin Invest 2002, 32 (Suppl 3): 14-23.Boden G, Shulman GI. Free acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and ®-cell dysfunction. Eur J Clin Invest 2002, 32 (Suppl 3): 14-23.Bollheimer L, Skelly R, Chester M, McGarry J, Rhodes C. Chronic exposure to free fatty acid reduces pancreatic beta cell insulin content by increasing basal insulin secretion that is not compensated for by a corresponding increase in proinsulin.Bollheimer L, Skelly R, Chester M, McGarry J, Rhodes C. Chronic exposure to free fatty acid reduces pancreatic beta cell insulin content by increasing basal insulin secretion that is not compensated for by a corresponding increase in proinsulin.Chandron M., Phillips S. A., Ciaraidi T., Henry R. R. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 2442-50.Chandron M., Phillips S. A., Ciaraidi T., Henry R. R. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 2442-50.Despres J-P, Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. Curr Opin Lipidol 1994; 5: 274-289.Despres J-P, Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. Curr Opin Lipidol 1994; 5: 274-289.Despres J-P. Inflammation and cardiovascular disease: is abdominal obesity the missing link? Int J Obes 2003, 27 (Suppl): 22-24.Despres J-P. Inflammation and cardiovascular disease: is abdominal obesity the missing link? Int J Obes 2003, 27 (Suppl): 22-24.Gillum R, Mussolino M, Madans J. Body fat distribution, obesity, overweight and stroke incidence in women and men: the NHANES I Epidemic Follow-up Study. Int J Obes Relat Metab Disord 2001; 25: 628-638.Gillum R, Mussolino M, Madans J. Body fat distribution, obesity, overweight and stroke incidence in women and men: the NHANES I Epidemic Follow-up Study. Int J Obes Relat Metab Disord 2001; 25: 628-638.Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tis- sue renin-angiotensin system in the pathophysiology of obesity and obesity-relat- ed disorders. Obesity Rev 2003, 4: 43-55.Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tis- sue renin-angiotensin system in the pathophysiology of obesity and obesity-relat- ed disorders. Obesity Rev 2003, 4: 43-55.Han T, van Leer E, Seidell J, Lean M. Waist Circumference Abdominal Sagittal Diameter. Best Simple Anthropometric Indexes of Abdominal Visceral Adipose Tissue Accumulation and Related Cardiovascular Risk in Men and Women. Am J Cardiol 1994; 73; 460-468.Han T, van Leer E, Seidell J, Lean M. Waist Circumference Abdominal Sagittal Diameter. Best Simple Anthropometric Indexes of Abdominal Visceral Adipose Tissue Accumulation and Related Cardiovascular Risk in Men and Women. Am J Cardiol 1994; 73; 460-468.Hauner H, Petruschke T, Russ M, et al. Effects of tumor necrosis factor alpha (TNF〈) on glucose transport and lipid metabolism of newly differentiated human fat cells culture. Diabetologia 1995, 38: 764-771.Hauner H, Petruschke T, Russ M, et al. Effects of tumor necrosis factor alpha (TNF〈) on glucose transport and lipid metabolism of newly differentiated human fat cells culture. Diabetologia 1995, 38: 764-771.Hern_ndez-Rodriguez J, Seragga M, Vilardell C, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis. Angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003, 107: 2428-2434.Hern_ndez-Rodriguez J, Seragga M, Vilardell C, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis. Angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003, 107: 2428-2434.Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004, 89(2): 447-460.Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004, 89(2): 447-460.Juhan-Vague I, Alessi C, Vague P. Thrombogenic and Fibrinolytic Factors and Cardiovascular Risk in non-insulin-dependent Diabetes Mellitus. The Finnish Medical society DUODECIM, Ann Med 1996; 28: 371-380.Juhan-Vague I, Alessi C, Vague P. Thrombogenic and Fibrinolytic Factors and Cardiovascular Risk in non-insulin-dependent Diabetes Mellitus. The Finnish Medical society DUODECIM, Ann Med 1996; 28: 371-380.Juhan-Vague I, Stephen D, Pyke M et al. Fibrinolitic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina Pectoris. Circulation 1996; 94: 2057-2063.Juhan-Vague I, Stephen D, Pyke M et al. Fibrinolitic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina Pectoris. Circulation 1996; 94: 2057-2063.Kalkhoff RD, Hartz AJ, Ruplay DC, Kissebah A, Kelber S. Relationship of body fat distribution to blood pressure, carbohydrate tolerance, and plasma lipids in healthy obese women. J Lab Clin Med 1983; 102: 621-627.Kalkhoff RD, Hartz AJ, Ruplay DC, Kissebah A, Kelber S. Relationship of body fat distribution to blood pressure, carbohydrate tolerance, and plasma lipids in healthy obese women. J Lab Clin Med 1983; 102: 621-627.Kissebah A, Krakower G. Regional adiposity and morbidity. Physiol Rev 1994; 74: 761-811.Kissebah A, Krakower G. Regional adiposity and morbidity. Physiol Rev 1994; 74: 761-811.Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sj_str_m L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12-year follow- up of participants in the population study of women in Gothenburg, Sweden. BMJ 1984; 289: 1261-1263.Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sj_str_m L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12-year follow- up of participants in the population study of women in Gothenburg, Sweden. BMJ 1984; 289: 1261-1263.Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105: 1135-1143.Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105: 1135-1143.Lindsay RS, Funahashi T, Habson RL et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360: 57-58.Lindsay RS, Funahashi T, Habson RL et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360: 57-58.Maeda N, Takanashi M, Funahashi T et al. PPAR© ligands increase expression and plasma concentration of adiponectin, an adipose-derived protein. Diabetes 2001, 50: 2094-2099.Maeda N, Takanashi M, Funahashi T et al. PPAR© ligands increase expression and plasma concentration of adiponectin, an adipose-derived protein. Diabetes 2001, 50: 2094-2099.Matsubara M, Maruoka S., Katayose S. Decreased plasma adiponectin concen- trations in women with dyslipidemia. J Clin Endocrinol Metab 2002; 87: 2764-9.Matsubara M, Maruoka S., Katayose S. Decreased plasma adiponectin concen- trations in women with dyslipidemia. J Clin Endocrinol Metab 2002; 87: 2764-9.Matsuzawa Y., Funahashi T., Nacamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999; 892: 146-54.Matsuzawa Y., Funahashi T., Nacamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999; 892: 146-54.Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998, 22: 1145-1158.Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998, 22: 1145-1158.Neel J, Julius S, Weder A et al. Syndrome X: is it for real? Genet Epidemiol 1998; 15: 19-32.Neel J, Julius S, Weder A et al. Syndrome X: is it for real? Genet Epidemiol 1998; 15: 19-32.Okamoto Y, Arita Y, Nishida M et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000, 32: 47-50.Okamoto Y, Arita Y, Nishida M et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000, 32: 47-50.Ouchi N., Kihara S, Nishida M et al. Adipocyte-derived plasma protein, adiponectin, suppress lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103: 1057-1063.Ouchi N., Kihara S, Nishida M et al. Adipocyte-derived plasma protein, adiponectin, suppress lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103: 1057-1063.Ouchi N., Kihara S., Arita Y. et al. Adiponectin, adipocyte-derived plasma protein, inhibits endothelial NF-kB signaling through camp-dependent pathway. Circulation 2000, 102: 1296-1301.Ouchi N., Kihara S., Arita Y. et al. Adiponectin, adipocyte-derived plasma protein, inhibits endothelial NF-kB signaling through camp-dependent pathway. Circulation 2000, 102: 1296-1301.Ouchi N., Kihara S., Arita Y. et al. Novel modulator for endothelial adhesion mol- ecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-6.Ouchi N., Kihara S., Arita Y. et al. Novel modulator for endothelial adhesion mol- ecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-6.Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep 2003, 3: 207-213.Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep 2003, 3: 207-213.Porter MH, Cuthins A, Fine JB, et al. Effects of TNF-〈 on glucose metabolism and lipolysis in adipose tissue and isolated fat-cell preparations. J Clin Med 2002, 139: 140-146.Porter MH, Cuthins A, Fine JB, et al. Effects of TNF-〈 on glucose metabolism and lipolysis in adipose tissue and isolated fat-cell preparations. J Clin Med 2002, 139: 140-146.Rabinovitch A, Suares-Pinzon WL. Cytokines and their roles in pancreatic islet ®-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998, 55: 1139-1149.Rabinovitch A, Suares-Pinzon WL. Cytokines and their roles in pancreatic islet ®-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998, 55: 1139-1149.Reaven G. M. Banting Lecture: role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.Reaven G. M. Banting Lecture: role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.Rexrode K, Buring J, Manson J. Abdominal and adiposity and risk of coronary heart disease in men. Int J Obes Relat Metab Disord 2001; 25: 1047-1056.Rexrode K, Buring J, Manson J. Abdominal and adiposity and risk of coronary heart disease in men. Int J Obes Relat Metab Disord 2001; 25: 1047-1056.Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifesta- tions of metabolic syndrome. Obesity Research 2004, 12 (2): 180-192.Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifesta- tions of metabolic syndrome. Obesity Research 2004, 12 (2): 180-192.Spranger J, Kroke A, M_hlig M et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003, 361: 226-228.Spranger J, Kroke A, M_hlig M et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003, 361: 226-228.Sun Z, Andersson R. NF-kB activation and inhibition: a review. Shock 2002, 18: 99-106.Sun Z, Andersson R. NF-kB activation and inhibition: a review. Shock 2002, 18: 99-106.Takanashi M, Funahashi T, Shimomura I et al. Plasma leptin levels and boby fat disribution. Horm Metab Res 1996, 28: 751-752Takanashi M, Funahashi T, Shimomura I et al. Plasma leptin levels and boby fat disribution. Horm Metab Res 1996, 28: 751-752Third Report of the National Cholesterol Education Progam (NCEP) Expert Panel on Detection, Evaluation and treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication 2001; 5. N 01-3670.Third Report of the National Cholesterol Education Progam (NCEP) Expert Panel on Detection, Evaluation and treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication 2001; 5. N 01-3670.Unger R H. Lipotoxic Diseases. Annu Rev Med 2002; 53: 319-36.Unger R H. Lipotoxic Diseases. Annu Rev Med 2002; 53: 319-36.Vague J. La diff_renciation sexuelle, facteur d_terminant des formes de l'obesit_. Presse Med 1947; 30: 339-340.Vague J. La diff_renciation sexuelle, facteur d_terminant des formes de l'obesit_. Presse Med 1947; 30: 339-340.Vanhala M G, Pitkajarvi T K, Kumpusalo E J, Takala J K. Metabolic syndrome in middle-aged Finnish population. J Cardiovasc Risk 1997; 4: 291-5.Vanhala M G, Pitkajarvi T K, Kumpusalo E J, Takala J K. Metabolic syndrome in middle-aged Finnish population. J Cardiovasc Risk 1997; 4: 291-5.Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86: 1930-1935.Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86: 1930-1935.Yokota T, Rreddy Mekka, Medina K L et al. Paracrine regulation of fat cell forma- tion in bone marrow cultures via adiponectine and prostaglandins. J Clin Invest 2002, 109: 1303-1310.Yokota T, Rreddy Mekka, Medina K L et al. Paracrine regulation of fat cell forma- tion in bone marrow cultures via adiponectine and prostaglandins. J Clin Invest 2002, 109: 1303-1310.Zinman B, Hanley A J G, Harris S B et al. Circulating tumor necrosis factor-〈 con- centrations in a native Canadian population with high rates of type 2 diabetes mel- litus. J Clin Endocrinolol Metab 1999, 84: 2172 2178.Zinman B, Hanley A J G, Harris S B et al. Circulating tumor necrosis factor-〈 con- centrations in a native Canadian population with high rates of type 2 diabetes mel- litus. J Clin Endocrinolol Metab 1999, 84: 2172 2178.

The authors declare that there are no conflicts of interest present.